Categories AlphaGraphs, Earnings, Retail
Earnings preview: What to expect when Tiffany reports Q1 2019 results
Tiffany & Co. (NYSE: TIF) is scheduled to report first quarter 2019 earnings results on Tuesday, June 4, before market open. Revenue is expected to dip down by 1.3% to $1.02 billion while earnings is estimated to decline over 11% to $1.01 per share. Looking at the past four quarters, Tiffany has topped earnings forecasts three times.
Tiffany is likely to face pressures on its top line during the first half of 2019 from weak demand among local customers as well as negative impacts on tourist spending due to strength in the US dollar. The threat from tariffs due to the ongoing US-China trade war also looms over the company.
Tiffany has been investing significantly in business growth initiatives which could help improve revenues going forward but in the meantime, the higher expenses could weigh on earnings.
For the fourth quarter of 2018, Tiffany beat earnings expectations but missed the mark on revenues. Both net sales and comparable sales dropped 1% due to lacklustre holiday results. Earnings jumped to $1.67 per share from $0.50 per share in the prior-year period helped by a lower tax rate.
For fiscal year 2019, Tiffany expects worldwide net sales to rise by a low-single-digit percentage over the prior year, while EPS is expected to increase by a mid-single-digit percentage. The company also expects a low-single-digit rise in full-year comparable sales, with eight store openings, six closings and 15 relocations.
According to a report by Research and Markets, global diamond jewelry sales in 2018 rose 4% to $85.9 billion from a year ago. Sales in North America made up more than 50% of the share of the total sales and were up 4% year-over-year. The report suggests that the diamond market has a large development space and is estimated to grow at a rate of 5-10% over the next five years.
Tiffany’s shares have gained 12% thus far this year but looking at the past three months, the stock has dropped 7%.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on